K. Tanimura

发表

Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report

Nozomi Tani, T. Takeda, Nobutaka Kataoka, 2021, Medicina.

The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study

K. Takayama, J. Uchino, M. Takeuchi, 2021, Frontiers in Oncology.

Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients

K. Takayama, J. Uchino, Tadaaki Yamada, 2020, Scientific Reports.

Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial

M. Fujita, K. Takayama, J. Uchino, 2018, Investigational New Drugs.

Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer

Tadaaki Yamada, K. Takayama, J. Uchino, 2019, Journal of clinical medicine.

The Impact of Immune-related Adverse Events on the Effect of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer

K. Takayama, J. Uchino, Tadaaki Yamada, 2019, Haigan.

The Proline-rich Akt Substrate of 40 kDa (PRAS40) Is a Physiological Substrate of Mammalian Target of Rapamycin Complex 1*

A. Nakashima, J. Avruch, U. Kikkawa, 2007, Journal of Biological Chemistry.

Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.

K. Takayama, Y. Iwasaki, Y. Kaneko, 2018, Anticancer research.

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer

K. Takayama, J. Uchino, Tadaaki Yamada, 2019, Cancer medicine.

Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer.

M. Horinaka, T. Sakai, S. Yano, 2021, Cancer letters.

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells

M. Horinaka, T. Sakai, S. Yano, 2022, Cancer medicine.

Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib

K. Takayama, Tadaaki Yamada, M. Hibino, 2021, Diagnostics.

Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients

K. Takayama, J. Uchino, Tadaaki Yamada, 2019, Cancers.

HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features

M. Horinaka, T. Sakai, Ryohei Katayama, 2022, npj Precision Oncology.

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer

M. Horinaka, T. Sakai, S. Yano, 2020, Clinical Cancer Research.

High levels of AXL expression in untreated EGFR ‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib

T. Mitsudomi, S. Yano, K. Takayama, 2022, Cancer science.

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

S. Yano, J. Uchino, M. Boroni, 2019, Nature Communications.

An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer

K. Takayama, J. Uchino, Tadaaki Yamada, 2018, Medicine.

Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study

Tadaaki Yamada, T. Kurata, H. Yoshioka, 2023, Cancers.

Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer

K. Takayama, J. Uchino, Tadaaki Yamada, 2019, Thoracic cancer.

Phase I/II Clinical Trial of Weekly Intraperitoneal Paclitaxel (IP-PTX) with Monthly Intravenous Carboplatin (IV-CBDCA) for Minimal Residual Disease of Ovarian, Tubal, and Peritoneal Carcinoma

S. Takeuchi, K. Tanimura, T. Miyamoto, 2019, Journal of Cancer Biology and Therapeutics.

Treatment rationale and design of the RAMNITA study

K. Takayama, J. Uchino, Tadaaki Yamada, 2018, Medicine.

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

S. Yano, K. Takayama, J. Uchino, 2019, Nature Communications.

Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial

J. Uchino, H. Kimura, K. Yoshimura, 2023, The oncologist.

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer

Young Hak Kim, M. Horinaka, T. Sakai, 2023, npj Precision Oncology.

Pulmonary Pleomorphic Carcinoma Harboring EGFR Mutation Successfully Treated with Osimertinib: A Case Report

T. Takeda, Nobutaka Kataoka, Yusuke Kunimatsu, 2022, Medicina.

Entrectinib for ROS1‐rearranged non‐small cell lung cancer after crizotinib‐induced interstitial lung disease: A case report

T. Takeda, Nobutaka Kataoka, Yusuke Kunimatsu, 2021, Respirology case reports.

Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer

T. Kijima, Tadaaki Yamada, M. Tamiya, 2023, JAMA network open.

TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study.

Tadaaki Yamada, Shinsaku Tokuda, T. Harada, 2023, JTO Clinical and Research Reports.

Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study

T. Kurata, R. Honda, T. Takeda, 2024, Frontiers in oncology.

Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status

Tadaaki Yamada, M. Tamiya, Shinsaku Tokuda, 2023, Targeted Oncology.

Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%

M. Tamiya, Shinsaku Tokuda, Yasuhiro Goto, 2024, Frontiers in immunology.

Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study

M. Tamiya, Shinsaku Tokuda, Yasuhiro Goto, 2024, Frontiers in immunology.